Current applications of multiparameter flow cytometry in plasma cell disorders

[1]  R. Hájek,et al.  Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity , 2017, Hematological oncology.

[2]  L. Arenillas,et al.  Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition , 2017, Haematologica.

[3]  A. Órfão,et al.  Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[5]  E. V. Van Allen,et al.  The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma , 2017, Cell reports.

[6]  C. Klein,et al.  Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. , 2017, Cancer cell.

[7]  N. Puig,et al.  Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma , 2017, Leukemia.

[8]  B. Barlogie,et al.  Differentiation stage of myeloma plasma cells: biological and clinical significance , 2017, Leukemia.

[9]  M. Gertz.  Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management , 2017, American journal of hematology.

[10]  A Orfao,et al.  Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma , 2017, Leukemia.

[11]  Quentin Lecrevisse,et al.  Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. , 2017, Blood.

[12]  D. Dingli,et al.  The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. , 2017, Blood.

[13]  P. Evans,et al.  Minimal residual disease is an independent predictor for 10-year survival in CLL. , 2016, Blood.

[14]  F. Prósper,et al.  Non-Invasive Genetic Profiling Is Highly Applicable in Multiple Myeloma (MM) through Characterization of Circulating Tumor Cells (CTCs) , 2016 .

[15]  F. Prósper,et al.  Genomic Profiles of Bone Marrow (BM) Clonal Plasma Cells (PCs) Vs Circulating Tumor Cells (CTCs) and Extramedullary (EM) Plasmacytomas in Multiple Myeloma (MM) , 2016 .

[16]  B. Barlogie,et al.  Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM) , 2016 .

[17]  J. Castillo,et al.  Plasma Cell Disorders. , 2016, Primary care.

[18]  T. Golub,et al.  Genetic interrogation of circulating multiple myeloma cells at single-cell resolution , 2016, Science Translational Medicine.

[19]  Bruno Paiva,et al.  Utility of flow cytometry studies in the management of patients with multiple myeloma , 2016, Current opinion in oncology.

[20]  M. Dimopoulos,et al.  Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia , 2016, British journal of haematology.

[21]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[22]  Eun Y. Lee,et al.  Abstract 3123: Aberrant expression of CD33 is associated with poor prognosis in patients with multiple myeloma and tumor progression , 2016 .

[23]  A. Órfão,et al.  Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. , 2016, Blood.

[24]  F. Prósper,et al.  Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. , 2016, Blood.

[25]  Marcos González,et al.  Origin of Waldenstrom's macroglobulinaemia. , 2016, Best practice & research. Clinical haematology.

[26]  D. Dingli,et al.  The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. , 2016, Leukemia research.

[27]  H. Goldschmidt,et al.  Flow cytometry‐based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis , 2016, Cancer medicine.

[28]  R. Hájek,et al.  Monoclonal antibodies - A new era in the treatment of multiple myeloma. , 2016, Blood reviews.

[29]  H. Olteanu.  Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma. , 2016, Surgical pathology clinics.

[30]  R. Hájek,et al.  Immunomodulatory drugs in AL amyloidosis. , 2016, Critical reviews in oncology/hematology.

[31]  K. Narita,et al.  Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response , 2016, Leukemia & lymphoma.

[32]  B. Paiva,et al.  Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting , 2016, Cytometry. Part B, Clinical cytometry.

[33]  A. Órfão,et al.  Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma , 2016, Cytometry. Part B, Clinical cytometry.

[34]  A. Órfão,et al.  Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition , 2016, Cytometry. Part B, Clinical cytometry.

[35]  A. Órfão,et al.  Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases , 2016, Cytometry. Part B, Clinical cytometry.

[36]  M. Boccadoro,et al.  Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents , 2016, Cytometry. Part B, Clinical cytometry.

[37]  J. Miguel,et al.  Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials , 2015 .

[38]  H. Goldschmidt,et al.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Galieni,et al.  Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard‐risk cytogenetics , 2015, British journal of haematology.

[40]  A. Órfão,et al.  The cellular origin and malignant transformation of Waldenström macroglobulinemia. , 2015, Blood.

[41]  N. Puig,et al.  The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma , 2015, Haematologica.

[42]  Y. Tai,et al.  Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients , 2015, Annals of Hematology.

[43]  D. Grimwade,et al.  Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? , 2014, Blood.

[44]  B. Barlogie,et al.  Curing myeloma at last: defining criteria and providing the evidence. , 2014, Blood.

[45]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[46]  A. Dispenzieri,et al.  Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma , 2014, Leukemia.

[47]  B. Pégourié,et al.  Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Dimopoulos,et al.  Solitary bone plasmacytomas need to flow. , 2014, Blood.

[49]  E. Colado,et al.  Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. , 2014, Blood.

[50]  R. de Tute,et al.  Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. , 2014, Blood.

[51]  M. Dimopoulos,et al.  Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients , 2014, American journal of hematology.

[52]  T. Cedena,et al.  Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. , 2014, Blood.

[53]  N. Puig,et al.  Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry , 2014, Leukemia.

[54]  M. Gulisano,et al.  CD200 expression in patients with Multiple Myeloma: another piece of the puzzle. , 2013, Leukemia research.

[55]  A. Órfão,et al.  Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. , 2013, Blood.

[56]  G. Morgan,et al.  Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  A. Brunner,et al.  Improved accuracy of discrimination between IgM Multiple Myeloma and Waldenström Macroglobulinaemia by testing for MYD88 L265P mutations , 2013, British journal of haematology.

[58]  H. Goldschmidt,et al.  Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project , 2013, Leukemia.

[59]  L. Staudt,et al.  MYD88 L265P somatic mutation in IgM MGUS. , 2012, The New England journal of medicine.

[60]  M. Terol,et al.  Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials. , 2012, The American journal of pathology.

[61]  A. Dispenzieri,et al.  High Levels of Peripheral Blood Circulating Plasma Cells as a Specific Risk Factor for Progression of Smoldering Multiple Myeloma , 2012, Leukemia.

[62]  T. Žvirblis,et al.  Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma , 2012, Leukemia & lymphoma.

[63]  M. Terol,et al.  Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients , 2012, Leukemia.

[64]  M. Dimopoulos,et al.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.

[65]  P. Hari,et al.  CD200 expression in plasma cell myeloma , 2011, British journal of haematology.

[66]  E. Ocio,et al.  The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. , 2011, Blood.

[67]  P. Sonneveld,et al.  Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. , 2011, Blood.

[68]  M. Pérez‐Andrés,et al.  CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features , 2011, Haematologica.

[69]  A. Órfão,et al.  Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia. , 2011, Clinical lymphoma, myeloma & leukemia.

[70]  F. Berrino,et al.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.

[71]  J. Miguel,et al.  Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell‐related disorders , 2010, Cytometry. Part B, Clinical cytometry.

[72]  Bernard Klein,et al.  Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138− and CD138+ plasma cells , 2010, Haematologica.

[73]  A. Órfão,et al.  Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells , 2010, British journal of haematology.

[74]  A. Órfão,et al.  The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. , 2009, Blood.

[75]  H. Asaoku,et al.  Constitutively lower expressions of CD54 on primary myeloma cells and their different localizations in bone marrow , 2009, European journal of haematology.

[76]  N. Karandikar,et al.  Immunophenotypic studies of monoclonal gammopathy of undetermined significance , 2008, BMC clinical pathology.

[77]  A. Órfão,et al.  Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. , 2008, Blood.

[78]  N. Munshi,et al.  Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. , 2008, Blood.

[79]  M. Terol,et al.  Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  Marina Ruggeri,et al.  Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders , 2008, Haematologica.

[81]  R. Kyle,et al.  Epidemiology of the plasma-cell disorders. , 2007, Best practice & research. Clinical haematology.

[82]  A. Órfão,et al.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. , 2007, Blood.

[83]  H. van de Velde,et al.  Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma , 2007, Haematologica.

[84]  T. Therneau,et al.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. , 2007, The New England journal of medicine.

[85]  Nitin J. Karandikar,et al.  Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. , 2007, American journal of clinical pathology.

[86]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[87]  A. Órfão,et al.  Conventional diagnostics in multiple myeloma. , 2006, European journal of cancer.

[88]  B. Geiger,et al.  Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration , 2006, British journal of haematology.

[89]  Terry M Therneau,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[90]  D. Dingli,et al.  Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. , 2005, Blood.

[91]  F. Magrangeas,et al.  CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target , 2005, Leukemia.

[92]  Robert A Kyle,et al.  Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. , 2005, Blood.

[93]  R. Fonseca,et al.  Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  R. Braylan,et al.  Impact of flow cytometry on the diagnosis and characterization of lymphomas, chronic lymphoproliferative disorders and plasma cell neoplasias , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[96]  Shaji K. Kumar,et al.  Bone marrow angiogenesis and circulating plasma cells in multiple myeloma , 2003, British journal of haematology.

[97]  M. Dimopoulos,et al.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[98]  A. Órfão,et al.  Immunophenotypic analysis of Waldenstrom's macroglobulinemia. , 2003, Seminars in oncology.

[99]  R. Fonseca,et al.  Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. , 2003, Blood.

[100]  G. Morgan,et al.  Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. , 2002, Blood.

[101]  A. Órfão,et al.  Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. , 2002, Blood.

[102]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[103]  S. Barrans,et al.  Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression , 1999, British journal of haematology.

[104]  R. Bataille,et al.  The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma , 1998, Leukemia.

[105]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[106]  Joan,et al.  Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. , 1998, The American journal of pathology.

[107]  Martine,et al.  CD28, a marker associated with tumoral expansion in multiple myeloma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[108]  A. Órfão,et al.  DNA cell content studies in multiple myeloma. , 1996, Leukemia & lymphoma.

[109]  J. Miguel,et al.  Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients , 1995, British journal of haematology.

[110]  P. Lacor,et al.  Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells , 1991, British journal of haematology.

[111]  D. Ferriman,et al.  Macroglobulinaemia , 1960 .

[112]  D. Dingli,et al.  Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression , 2017, Leukemia.

[113]  B. Paiva,et al.  Multiple Myeloma Minimal Residual Disease. , 2016, Cancer treatment and research.

[114]  M. Terol,et al.  A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control , 2013, Leukemia.

[115]  M. Terol,et al.  High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. , 2012, Blood.

[116]  B. Hallberg,et al.  c-Kit--a hematopoietic cell essential receptor tyrosine kinase. , 2007, The international journal of biochemistry & cell biology.

[117]  J. Bladé.  Clinical practice. Monoclonal gammopathy of undetermined significance. , 2006, New England Journal of Medicine.

[118]  Lawrence R. Johnson,et al.  Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. , 2003, Archives of pathology & laboratory medicine.

[119]  T. Grogan,et al.  Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). , 1990, Blood.